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ABSTRACT
Glioblastoma (GBM) cells are characterized by high phagocytosis, lipogenesis, 
exocytosis activities, low autophagy capacity and high lysosomal demand are 
necessary for survival and invasion. The lysosome stands at the cross roads of lipid 
biosynthesis, transporting, sorting between exogenous and endogenous cholesterol. 
We hypothesized that three already approved drugs, the autophagy inducer, sirolimus 
(rapamycin, Rapa), the autophagy inhibitor, chloroquine (CQ), and DNA alkylating 
chemotherapy, temozolomide (TMZ) could synergize against GBM. This repurposed 
triple therapy combination induced GBM apoptosis in vitro and inhibited GBM 
xenograft growth in vivo. Cytotoxicity is caused by induction of lysosomal membrane 
permeabilization and release of hydrolases, and may be rescued by cholesterol 
supplementation. Triple treatment inhibits lysosomal function, prevents cholesterol 
extraction from low density lipoprotein (LDL), and causes clumping of lysosome 
associated membrane protein-1 (LAMP-1) and lipid droplets (LD) accumulation. Co-
treatment of the cell lines with inhibitor of caspases and cathepsin B only partially 
reverse of cytotoxicities, while N-acetyl cysteine (NAC) can be more effective. A 
combination of reactive oxygen species (ROS) generation from cholesterol depletion 
are the early event of underling mechanism. Cholesterol repletion abolished the ROS 
production and reversed the cytotoxicity from QRT treatment. The shortage of free 
cholesterol destabilizes lysosomal membranes converting aborted autophagy to 
apoptosis through either direct mitochondria damage or cathepsin B release. This 
promising anti-GBM triple therapy combination severely decreases mitochondrial 
function, induces lysosome-dependent apoptotic cell death, and is now poised for 
further clinical testing and validation.
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INTRODUCTION
GBM is an aggressive malignancy with high mortality, 
and relative resistance to radiation and other treatments 
[1, 2]. Current treatments include maximal surgery followed 
by adjuvant radiation (RT) and chemotherapy (CT) with 
TMZ [3]. The addition of bevacizumab to standard RT-
TMZ therapy did not improve overall survival. Pre-clinical 
data suggest that this failure may be due to tumor metabolic 
adaptation toward anaerobic metabolism, and increased 
tumor cell invasiveness after anti-angiogenic treatment 
[4, 5]. These represent examples of adaptive stress-response 
by the tumor and therefore therapies that induce and amplify 
tumor stress response, such as autophagy, unfolded protein 
response (UPR) and cancer metabolism, represent potential 
therapeutic strategies.
GBM is characterized by exaggerated lipogenesis, 
enhanced LDL cholesterol uptake, high phagocytosis and 
micro-vesicle exocytosis activities, and depends very 
much on cholesterol homeostasis for constant membrane 
changes. The majority of cholesterol is found at the plasma 
membrane, enriched as raft micro-domain, while the 
endoplasmic reticulum (ER), mitochondria and lysosomes 
contain minimal amount of cholesterol. The lysosome is on 
the end point of endocytic, phagocytic and autophagocytic 
pathway and responsible for their cellular trafficking and 
play the key role in maintain cholesterol homeostasis. 
Because of blood brain barrier, GBM cells constantly 
require cholesterol from tumor microenvironment (TME), 
its high lysosomal demand may be an “Achilles’ heel”, 
an exploitable vulnerability of GBM [6, 7]. Recently, 
Villa et al. also showed that GBM cells are dependent on 
cholesterol for survival, and succumb to Liver X receptor 
(LXR) agonist-induced cholesterol depletion by decreased 
influx and increased efflux of cholesterol [8]. GBM cells 
can convert excessive cholesterol to cholesterol ester 
for storage in LD, which were mobilized to fuel fatty 
acid oxidation to sustain cell viability during nutrient 
deprivation stress [9]. The suppression of LD formation 
or the de novo cholesterol synthesis all had been reported 
to suppress GBM growth [10, 11]. We try to disturb the 
Achilles’ heel with autophagy modulation.
Compared to lower grade gliomas, GBMs express 
lower intrinsic autophagy activity, whereas higher expression 
of autophagy genes, LC3 and Beclin1 correlates with better 
survival [12]. High grade glioma has insufficient autophagy 
due to promoter hyper-methylation and downregulation of 
the autophagy inducer ULK2, resulting in tumor growth 
[13]. Lysosomes are primarily involved in the degradation, 
recycling and secretory pathways for nutrient homeostasis 
[14]. All of the inter-connections between membrane and 
intracellular organelles require cholesterol homeostasis. 
Intracellular cholesterol trafficking is very important for 
normal ER and lysosome functions [15]. Lower tumor 
autophagy activity is compensated with higher tumor 
phagocytic activity to obtain nutrition from TME and higher 
lysosomal exocytosis for clearance of ER oxidative stress 
[16]. We hypothesized that cholesterol trafficking between 
the plasma membrane and intracellular compartments is also 
a required cellular process that could also be disrupted by the 
paradoxical combination of autophagy inducers (rapamycin, 
Rapa) and inhibitors (Chloroquine, CQ). Synergistic effects 
of this paradoxical combining had reported work in many 
tumors such as melanoma, bladder cancer, colon cancer, 
hepatoma, sarcoma and glioma [17–23]. In general, the 
double combination may not be lethal unless elevated ER 
stress is also present. Therefore, we proposed and started 
testing a new “triple combination” therapeutic strategy 
against a variety of cancers by combining the autophagy 
inducer/inhibitor regimen with chemo- or radiotherapy 
to induce ER stress. We have reported clinical safety and 
promising efficacy for this triple combination strategy in 
a variety of cancer patients including GBM patients, who 
received standard of care TMZ plus RT (that induce ER 
stress) with CQ and Rapa [24, 25]. 
The stress from TMZ treatment combined with 
mTOR inhibition with Rapa treatment increases autophagy 
demand, but CQ inhibits lysosome degradation and the 
aborted autophagy increased the mitochondria burden. 
CQ plus Rapa treatment decreases the glycolytic and 
oxygen consumption rates, and inhibits the conversion of 
cholesterol ester to free cholesterol and lipolysis from LD 
resulting in cholesterol depletion destabilizes lysosomes 
and causing cathepsin release. LD accumulation is a sign 
of impaired mitochondria function [9]. The shortage of 
fatty acid for β-oxidation resulted in energy crisis and 
further potentiates the mitochondria burden and oxidation 
damage and converts tumor cells to apoptosis. 
RESULTS
CQ, Rapa and TMZ combination treatment 
synergistically increase apoptotic cell death, 
inhibits cell proliferation in GBM cell lines
We investigated the effect of CQ (Q), Rapa 
(R) and TMZ (T) combination treatment on cellular 
apoptosis and viability in 4 GBM cells lines. As shown 
in Figure 1A, induction of apoptotic cell death is most 
significant with the presence of CQ in all combinations 
(Q, QR, QT and QRT), slightly in RT treatment, but 
not with R, and T treatments. QRT treatment resulted in 
the highest level of apoptotic cell death in all GBM cell 
lines. In apoptotic cell death, a clear difference emerged 
in the pattern of cell death across the GBM cell lines, 
dividing the cell lines into two groups. Group I cells, 
GBM8401 and M059K displayed less sensitivity to 
TMZ treatment, QR treatment was pretty toxic to them 
and were not induced more apoptotic cell death after 
QRT treatment (Figure 1A). Group II cells, U87MG and 
Hs683 showed more sensitive to TMZ treatment. QRT 
treatment significantly increased apoptosis comparison 
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with QR and QT treatment. Expression of PARP and 
cleavage caspase-3 were showed in QR/QRT treatment 
of Type-I GBM cell lines and T/QT treatment of Type-II 
GBM cell lines (Figure 1B). Hypermethylation of the O6-
methylguanine-DNA- methyltransferase (MGMT) gene 
has been shown to be associated with better response to 
TMZ. However, the MGMT promoter methylation status 
in these GBM cell lines were not associated with TMZ 
sensitivity (Supplementary Figure 1A). We, therefore, 
chose GBM8401 and U87MG as representative of these 
two types for further studies. The QRT combination 
significantly inhibited cell proliferation especially on 
U87MG cells compared with GBM8401 cells (Figure 1C). 
Results of dose-dependent experiments were present 
in supplementary results (Supplementary Figure 1B). 
Pre-treatment with caspase 3 inhibitor z-VAD-FMK 
(10 uM treatment for 1 h) can only partially reverse the 
cytotoxicity in QT treated U87MG (Figure 1D) but not 
others. Consequently, QRT synergism were caspase-3 
independent in GBM8401 and U87MG cell lines. 
Both cell lines had basal LC3II and p62 expression. 
Accumulation of LC3II and p62 universally increased 
with addition of CQ, suggesting that both cell lines 
are moderately sensitive to autophagy inhibition 
(Figure 2A). In GBM8401 and U87MG, QR and QRT 
treatment decreased p-Akt activity more than with 
CQ alone or QT combination (Figure 2B). Rapamycin 
indeed inhibit p-p70S6k expression in both cell lines 
(Figure 2C). Interestingly, CHOP expression was only 
moderately increased after TMZ treatment with or without 
combination therapies, suggesting that ER stress does not 
significantly contribute to GBM cell death (Figure 2C 
and 2D). Rapa increased autophagy and decreased CHOP 
in both GBM lines, but GRP78 expression was only 
observed in U87MG cells after Rapa treatment, suggested 
a GRP78-induced autophagy process. 
CQ, Rapa and TMZ combination treatment 
induced oxidative stress and mitochondrial 
damage through energy crisis 
To investigate whether ROS induction plays a 
major role in cell death after treatment with QRT. We 
found treatment with Q, R alone or QT, QR or QRT 
markedly increased ROS generation except T (Figure 3A). 
Importantly, 20 mM NAC provided moderate to complete 
protection against Q, QR, QT, and QRT treatment in both 
GBM8401 and U87MG (Figure 3B), which indicated 
that ROS generation played early and imperial role in 
QR toxicities. Cells cultured with Q alone or QR, QRT 
treatments all showed significant loss of MMP (Figure 3C), 
Rapa alone increased ROS generation but did not lead 
to loss of MMP. GBM cells are characterized by high 
glycolytic activity and mitochondrial dysfunction [26]. 
Metabolic changes were investigated with the GBM8401 
cell line. As shown in Figure 3D, the OCR was decreased 
with all combinations except TMZ alone (Figure 3D, 
left panel). QRT combination resulted in most severe 
OCR impairment, with almost complete elimination 
of mitochondrial function. In an ECAR assay, similar 
decreases in glycolytic function were observed with CQ, 
Rapa, RT, QT, with the most significant depression observed 
with the QRT combination (Figure 3D right panel). These 
results indicated that QRT treatment induced by oxidative 
stress on both cells while GBM8401 was more vulnerable 
to mitochondria induced metabolic catastrophe. 
CQ, Rapa and TMZ combination destabilizes 
lysosomes and abrogates lipid droplets 
breakdown
Autophagy inhibition-mediated cellular apoptosis 
was recently reported to correlate with lysosomal cell 
death [27]. CQ is known to induce apoptosis by lysosomal 
membrane permeabilization, cathepsin release, and 
activation of BH3 interacting-domain death agonist 
(BID) and caspases [28, 29]. mTORC1 inhibitors such 
as Rapa decrease cholesterol biosynthesis and cause 
rapid lysosome cell death [23]. We investigated whether 
multiple autophagy modulations change lysosomal 
function. Figure 4A show abundant clumping and swelling 
of lysosomes with accumulation of LAMP-1 after Q, QR, 
QT and QRT treatment. The increased cathepsin B release 
from lysosomal swelling was suggested. Accordingly, we 
treated cathepsin inhibitor to observe whether cathepsin 
B dependent cell death played a major role. GBM8401 
and U87MG were pretreated with cathepsin inhibitor for 
1 h before treating them with Q, R, T and combination for 
24 h. As shown in Figure 4B, in U87MG cells pretreated 
with cathepsin inhibitor, cell viability was significantly 
increase in Q, QR, QT and QRT treatment. However, 
GBM8401 cells were partially recovered cell viability in 
only Q treatment. These finding indicated that U87MG 
cells is more vulnerable to lysosome cell death, while as 
previously described, the GBM8401 deceased mainly by 
mitochondria cell death mechanism. 
When free cholesterol increases, cholesteryl esters 
(CE) are formed and sequestered into LDs [30]. The 
breakdown of LDs is attributed to the actions of cytosolic 
hydrolytic enzymes or lipases. Recently, several studies 
have demonstrated an association between the lysosomal 
degradative pathway of autophagy (lipophagy) and 
the breakdown of intracellular LDs stores as survival 
mechanism [9, 31]. It was reported glioma cells 
accumulate LDs under hypoxic conditions, and this is 
directly correlated with the degree of malignancy and 
tumor growth [32]. To determine the change in LDs from 
baseline to post-treatment, GBM cells were visualized 
with fluorescent lipid dye BODIPY 493/503. In Figure 4C, 
LDs observed in GBM8401 cells slightly decreased after 
Rapa or RT treatment compared to untreated controls, 
suggesting that Rapa-induced lipophagy processes lead to 
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Figure 1: Effect of CQ (Q), Rapa (R) and TMZ (T) in different combination treatment on apoptosis and proliferation 
in 4 GBM cell lines. All GBM cell lines were cultured as following treatment to assay apoptotic cells (GBM8401 Q 40/R 12.5/T 400 μM 
24 h, M059K Q90/R 20/T 400 μM 24 h, U87MG Q 40/R 10/T 400 μM 48 h, Hs683 Q 15/R 20/T 400 48 h. (A) The population of annexin 
V+ apoptotic cells was evaluated by flow cytometry using annexin V-FITC/PI staining in GBM8401 cells, M059K, U87MG and Hs683 
cells  after CQ, Rapa and TMZ treatment. (B) The expression of cleaved PARP and cleavage caspase-3 in GBM8401 M059K, U87MG 
and Hs683 cells were analyzed by western blotting. (C) Cell proliferation in GBM8401 cells and U87MG cells after CQ, Rapa and TMZ 
treatment was assessed by MTS assay. The Y-axis represents the proliferation rate, calculated as the ratio to control untreated cells. The 
graphs shown represent the mean ± SE of at least three different experiments. (D) All GBM cell lines were treated CQ, Rapa, and TMZ 
in different combination following 1 h caspase-3 inhibitor (z-VAD-FMK) pretreatment and then assessed for cell viability. Statistical 
significance of CQ or Rapa or TMZ or combinations vs DMSO is indicated (*).  Statistical significance of CQ or Rapa or combinations vs 
TMZ alone is indicated (#). Statistical significance of QRT vs QR is indicated ($). Statistical significance: *P < 0.05, **P < 0.01; #P < 0.05, 
##P < 0.01, $P < 0.05.
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the breakdown of LDs. On the contrary, CQ contributed 
to marked LDs accumulation from aborted lipophagy, and 
TMZ resulted in modest LD accumulation - possibly a 
resistance mechanism to hydrophobic drug [33].
QRT treatment disturbs lipid droplet utilization 
and cholesterol homoeostasis
We observed a marked increase in GBM expression 
of low-density lipoprotein receptor (LDLR) in response to 
the free cholesterol deficit after Q, QR, or QRT treatments 
(Figure 5A). CQ inhibits the conversion of endocytosed 
LDL to free cholesterol, and limited the lipophagy process 
from LD. The majority of the available free cholesterol is 
likely required for active cell membrane repair, to maintain 
cell membrane integrity because of increased exocytosis 
after triple combination treatment. The absence of ATP-
binding cassette subfamiliy A membrane 1 (ABCA1), 
a cellular cholesterol efflux transport, overexpression 
after QRT triple combination treatment suggests that 
there was no associated efflux of cholesterol through 
this transporter (Figure 5A). We used filipin to visualize 
cellular cholesterol in three-drug treatment. The results 
show that decrease of membrane cholesterol in Q, QR, 
QT and QRT treatment in both cell lines and cholesterol 
treatment rescues partial membrane cholesterol in QRT 
treatment (Figure 5B). The data showed that Q, T, QT 
and QRT treatments result in increased exosome release, 
suggesting that free cholesterol efflux might occur through 
this pathway (Supplementary Figure 2). Interestingly, 
addition of free cholesterol decrease lysosome swelling 
(Figure 5C), rescued tumor cells viability (Figure 5D), and 
the LDLR overexpression was not observed (Figure 5E). 
LXR was not activated after CQ treatment (Figure 5E). 
Previous results showed cell death in Q, QR, QT and QRT 
treatment from ROS production (Figure 3B), while the 
additional free cholesterol significantly decreased ROS 
in in GBM8401 after Q, QR, QT, and QRT treatment 
(Figure 5F). Similar result was observed in U87MG (data 
not show). The results indicated that cell death of QRT 
treatment closely related to cholesterol depletion and ROS 
production. Cell membrane associated NADPH oxidase 
activation is suspected [34, 35]. 
The triple combination treatment effectively 
treats GBM orthotropic xenografts
To further evaluate the efficacy of QRT triple 
treatment, NOD/SCID mice bearing intracranial 
GBM8401 xenografts were treated. After 7 days 
implantation GBM8401, intra-peritoneal injections of 
TMZ alone, QR or QRT were performed from day 8 to day 
15. Tumor progression was evaluated with IVIS imaging 
over time as Figure 6A mentioned. A representative 
photo image was presented in Figure 6A. Tumor cells 
rapidly proliferate in untreated controls. Inhibition of 
tumor cell growth is observed QRT treatment, and there 
was significantly decrease tumor growth in QRT triple 
treatment (Figure 6B). QRT treatment was prolonged 
survival time comparison with other treatments 
(Figure 6C). We sacrificed mice on day 15 based on 
IACUC recommendations, loss of 25–30% of initial body 
Figure 2: Autophagy, ER stress, and p-AKT change after CQ (Q), Rapa (R) and TMZ (T) in different combination 
treatment.  GBM8401 cells and U87MG cells were treated with CQ, Rapa and TMZ in different combinations, harvested at 24 hours and 
immunoblotted for LC3-I, LC3-II and (A) p62, (B) p-AKT, (C) p-mTOR and p-S6K, (D) GRP78 and CHOP. 
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Figure 3: The metabolic change after CQ (Q), Rapa (R) and TMZ (T) in different combination treatment. Cells were 
treated CQ (90 or 40 μM), Rapa (12.5 or 10 μM) and TMZ (400 μM) for 24 h or 48 h. (A) ROS generation in GBM8410 and U87MG 
were detected by BD Accuri™ C6 flow cytometer. Date were processed and analyzed with BD Accuri™ C6 software. GBM8401 and 
U87MG cells were treated with or without 20 mM NAC.  (B) Apoptosis was assessed for analysis. (C) Loss of mitochondria membrane 
potential (MMP) was assessed via JC-1 staining and flow cytometry in GBM8401 and U87MG cells. The percentage of cells with low JC-1 
fluorescence is shown. (D) Mitochondrial respiration and glycolytic capacity in GBM8401 Left panel: evaluation of OXPHOS capacity of 
GBM8401 cells were plated at 1 × 105/well and cultured with each conditions for 2 h. Metabolic responses were evaluated after sequential 
injection of the following metabolic toxins: oligomycin, FCCP, antimycin A/rotenone. Right panel: evaluation of the glycolytic capacity of 
GBM8401 cultured with each conditions for 2 h. Metabolic responses were evaluated after sequential injection of the following metabolic 
toxins: Glucose, oligomycin and 2-DG. Statistical significance of CQ or Rapa or TMZ or combinations vs DMSO is indicated (*). Statistical 
significance of CQ or Rapa or combinations vs TMZ alone is indicated (#). Statistical significance of CQ or Rapa or TMZ or combinations 
vs QRT is indicated ($). Statistical significance: *P < 0.05, **P < 0.01; #P < 0.05, ##P < 0.01, $P < 0.05.
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Figure 4: Lysosomal swelling and lipid droplets (LDs) accumulation after CQ (Q), Rapa (R) and TMZ (T) in different 
combination treatment. (A) Immunostain with LAMP1 (a lysosome marker, green) and cathepsin B (red), quantified using Image J. 
(B) GBM cell lines were preincubated with cathepsin inhibitor (5 μM) for 1 h before the addition of CQ, Rapa and TMZ. Histograms show 
quantification of cell viability at day 1 (GBM8401) and day 2 (U87MG). (C) The change of LDs in U87MG and GBM8401 after CQ, Rapa 
and TMZ combination for 24 hrs. LDs was staining by BODIPY 493/503 (green) and Hoechst 33342 (nuclear, blue). Histograms were 
showed quantification of accumulation LDs by BODIPY 493/503 staining using flow cytometry. Statistical significance of CQ or Rapa or 
TMZ or combinations vs DMSO is indicated (*). Statistical significance: *P < 0.05, **P < 0.01. Scale bar: 10 μm.
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Figure 5: Changes of cholesterol homeostasis under CQ (Q), Rapa (R) and TMZ (T) in different combination treatment. 
(A) The expression of ABCA1, LDLR after different drug combinations for GBM 8401 cells and U87MG cells. (B) Cholesterol stain assay. 
GBM8401 cells and U87MG cells were treated, fixed and stained with filipin to visualize cholesterol (green). High-magnification imaging 
reveals that addition of free cholesterol (10 μg/mL) regains partial cell membrane under QRT treatment (whit arrow line display rich 
cholesterol cell membrane; yellow arrow line display lacking cholesterol cell membrane). (C) Salvage treatment with free cholesterol and 
stained for LAMP-1 (green). Representative images are shown alongside the quantification of lysosome swelling. (D) The added of free 
cholesterol with different drug combinations could recover cell survival. (E) Decreased LDLR expression and increase ABCA1 expression 
was noted, but the expression of LXR were not change. (F) ROS production was decreased after free cholesterol in Q, QR, QT, QRT 
treatments in GBM8401 cells.  Statistical significance is indicated (*). Statistical significance: *P < 0.05, **P < 0.01. Scale bars represent 
10 μm.
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weight should be considered as death with euthanasia 
administered according to institutional guidelines. 
DISCUSSION
This study suggests that GBM is susceptible to the 
induction of cholesterol depletion related to the lysosome 
dysfunction. High cholesterol turnover is essential for 
the survival of GBM cells under stress. In comparison to 
mTOR inhibitor (Rapa) treatment alone, the combined 
Rapa and lysosome inhibitor (CQ) with or without TMZ 
therapy significantly increased apoptotic cell death 
through mitochondria damage before cathepsin released 
from lysosome in one type of GBM cells (GBM8401), 
while the addition of TMZ decidedly increased apoptotic 
cell death through cathepsin induced cell death in other 
type of cells (U87G). We observed that triplet combination 
(QRT) treatment is synergistic in all type of GBM cells 
through depleted membrane cholesterol content along with 
ROS formation and the cytotoxicity can be reversed by 
external added cholesterol or NAC antioxidant. 
 Malignant glioma has a high lipid anabolism 
phenotype, enabling rapid cell proliferation [36–38]. 
Lipids, such as phospholipids, fatty acids, cholesterol, 
triglycerides and cholesterol esters, and sphingolipids, 
are important components of cells including the 
caveolin membrane system [15]. Most brain cholesterol 
is synthesized de novo in normal astrocytes, because 
cholesterol in the bloodstream cannot be transported 
across the blood brain barrier. GBM cells rely on uptake 
of exogenous cholesterol from neighboring cells [8]. 
Increased cholesterol esterification and storage in LD, 
in addition to increased LDL uptake are beneficial for 
GBM [10]. Cellular cholesterol levels are controlled 
by biosynthesis, cellular LDL uptake through LDL 
receptors, phagocytosis and efflux from cells. Lipid 
breakdown leads to release of free fatty acids that sustain 
β-oxidation in the mitochondria. As shown in Figure 2A 
through 4C, we observed an autophagy activation as 
evident by suppression of p70S6K phosphorylation 
with increased ROS production and a decreased LD 
after Rapa treatment. CQ markedly increased LC3B-II 
Figure 6: Decreased tumor growth with in vivo treatment of GBM xenograft model monitored by bioluminescence 
imaging. (A) The treatment schedule of GBM xenograft. GBM8401-luc cells (2 × 105) were injected stereotactically implanted into a 
single defined left hemisphere location (6 weeks old, n > 4) and the bioluminescence signal was monitored by the in vivo imaging system 
at the indicated days after inoculation. Seven days after tumor implanted received no treatment (control), treatment with TMZ (T, 50 mg/kg 
i.p.), CQ (50 mg/kg i.p.) + Rapa (5 mg/kg i.p.) (QR) and QRT. Tumor cells spread rapidly in the untreated control mice. When the 
intracranial brain tumors were treated with TMZ alone or QR, in both cases are similar patterns of untreated control. Tumor treatment by 
QRT significant slowed the growth of the tumors by day 4 after implantation. (B) Mice of QRT treatment significantly inhibit tumor growth 
compared with control, TMZ, and QR treatment. (C) QRT treatment was prolonged survival time. Statistical significance: Control vs QRT 
(*), T vs QRT (#), QR vs QRT ($). 
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conversion, p62 accumulation, lysosome clumping and 
LD accumulation, which indicated of lysosome blockage. 
Rapa treatment mimicked a state of nutritional starvation, 
the simultaneous combined autophagy inducer and 
inhibitor as QR treatment resulted in marked lysosomal 
swelling and LD accumulation. Because cells depended 
on LD fueled fatty acids for survival during nutrient 
deprivation [9]. Lippincott-Schwartz et al. showed that 
fatty acids are released from LDs by lipolysis and taken 
up by fused LDs with mitochondria to support oxidative 
respiration [39]. However, does fatty acid move from 
LD due to cytoplasmic lipase-mediated lipolysis instead 
of lipophagy, and how fatty acid trafficking after QR or 
QRT treatment causes mitochondria change are interesting 
issues for further study [39, 40]. 
In GBM cells, endolysosomes are required for 
digesting extracellular lipoproteins after endocytosis, 
and autophagy-mediated LD degradation also required 
lysosomes for lipid mobilization. The high dependence of 
GBM cells on lysosomes for lipid metabolism, coupled 
with their limited autophagy capacity makes GBM cells 
more vulnerable to CQ treatment-related cholesterol 
deficit. Maintaining cellular free cholesterol levels is 
essential for cell membrane maintenance, viable tumor 
cell morphology and lysosome function. CQ blocks 
cholesterol extraction from LDL contained in endosomes 
and from lipid droplets by inhibiting lysosomal function. 
CQ has long been known to increase rapid retrograde 
LDL exocytosis and delay the hydrolysis of cholesterol 
esters [39, 41]. Higher cholesterol efflux in GBM 
cells through increased exocytosis instead of ABCA1 
transporter are evident from exosome release after QT 
treatment. Since de novo cholesterol synthesis is also 
depressed with addition of Rapa-mediated SREBP 
down-regulation, adequate cholesterol reserves are not 
available to tumor cells. Triple QRT treatment results in 
accumulation of cholesterol esters in lipid droplets and 
failure of cholesterol mobilization upon ester hydrolysis, 
which significantly reduces availability of free cholesterol 
in tumor cells. Cellular cholesterol content directly 
influences lysosomal stability, and the increased lysosomal 
membrane permeability results in cathepsin release and 
increases apoptosis. The production of ROS is closely 
associated with cholesterol levels. NADPH oxidase is one 
of the main ROS-generating enzymes present in lipid rafts 
and both cholesterol content [34]. As shown in Figure 5, 
cholesterol repletion abolished the ROS production and 
reversed the cytotoxicity from QRT treatment. 
The Warburg effect of utilizing aerobic glycolysis as 
the primary supplier of ATP is found in GBM and many 
cancers. However, oxidative phosphorylation (OXPHOS) 
function is very important in GBM cells. A prior study 
showed that glioma stem cells are less glycolytic and use 
mitochondria for glucose oxidation in vivo [42–44]. Recent 
studies of orthotropic GBM xenografts demonstrated that 
GBM uses both glycolysis and mitochondrial oxidation for 
glucose catabolism. As shown in Figure 3D, the Rapa and CQ 
double combination has dual inhibitory action on OCR and 
ECAR, while the mitochondria function was most severely 
impaired. The decreased ATP supply further increases 
cellular dependence on autophagy functions. Simultaneous 
targeted disruption of multiple important cellular metabolism 
pathways may synergize to result in ‘synthetic lethality’. 
A recent phase II GBM clinical trial failed to show 
benefit after addition of everolimus, a Rapa analogue, to 
the standard TMZ regimen [45]. Activation of autophagy 
alone seems to be insufficient to reverse GBM therapeutic 
resistance. Our proposed approach of adding the 
autophagy inhibitor CQ appears to be more promising. A 
small randomized trial demonstrated the survival benefit of 
adding CQ to a combination of radiotherapy and lomustine 
in newly diagnosed GBM patients [46]. Rapa and CQ 
has been reported to own the ability to penetrate blood-
brain barrier [47, 48]. The present study demonstrates 
that cholesterol depletion may be a potential therapeutic 
mechanism of CQ that overcomes limitations in caspase-
dependent apoptotic cell death. Therefore, this study 
suggests that triple therapy of Rapa, CQ and standard 
TMZ-RT treatment would be a promising therapeutic 
strategy to test in clinical trials for GBM patients.
MATERIALS AND METHODS
Cell culture
GBM8401 cells, kindly provided by Professor 
Hsin-Ell Wang (Department of Biomedical Imaging and 
Radiological Sciences, National Yang-Ming University, 
Taiwan). U87MG cells, M059K cells, and Hs683 cells 
were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). U87MG were cultured in MEM 
with 1 mM Na pyruvate, 10% FBS and antibiotics (100 U/
ml penicillin and 100 μg/ml streptomycin). GBM8401 were 
cultured in RPMI with 10% FBS and antibiotics (100 U/
ml penicillin and 100 μg/ml streptomycin). M059K were 
cultured in MEM with 10% FBS, 0.1 mM NEAA, 1 mM 
sodium pyruvate. Hs683 were cultured in DMEM/F12K 
with 10% FBS, 0.05 mM MEAA, 0.5 mM sodium pyruvate. 
Cells were grown in a 5% CO2 incubator at 37°C. 
Cell proliferation assay
Cell cultures was performed by seeding at a density 
of 1.0 × 105 cells/well in 96-well round-bottom plates 
(Falcon, UK) containing 200 µL of medium. Various doses 
of chemotherapeutic drugs and CQ, in combination with 
Rapa (at different molar ratios) were added after tumor cells 
reached 1 × 106 density. Treated tumor cells were maintained 
for two days at 37°C in humidified 5% CO2. The rate of cell 
proliferation was measured using an MTS assay (CellTiter 
96 aqueous one-solution cell proliferation assay; Promega, 
WI, USA). 40 µL of CellTiter 96 aqueous one-solution 
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were added to each well. After 4 h of incubation, the UV 
absorbance of the solution was measured at a wavelength 
of 490 nm. All MTS assays were performed in triplicate.
Apoptosis assay
Apoptosis was assayed using an Annexin V Apoptosis 
Kit (BD Pharmingen, CA, USA) according to manufacturer 
instructions. Briefly, tumor cells were washed three times 
with PBS, then immediately analyzed for apoptosis using 
Annexin V/PI (propidium iodide) staining. Washed cells were 
supplemented with 1% BSA, then directly stained with 10 µL 
of PI and 2.5 µL Annexin V-FITC after adding 222.5 µL of 
binding buffer. Immediately following a 10 min incubation 
period in the dark on ice, the cells were analyzed by flow 
cytometry. The percentage of positive cells was determined 
by using a BD Accuri™ C6 and BD Accuri™ C6 software 
(Becton Dickinson, Mountain View, CA, USA).  
Western blot analysis
For protein analysis, cells were lysed for 5 min at 
room temperature in a buffer composed of 150 mM NaCl, 
50 mM Tris (pH 8.0), 5 mM EDTA, 1% (v/v) Nonidet 
p-40, 1 mM phenylmethylsulfonyl fluoride, 20 µg/mL 
aprotinin, and 25 µg/mL leupeptin (Sigma). The total 
protein concentration of lysates was measured using the 
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). 
Cell lysate (100 µg) was electrophoresed on a 12% 
polyacrylamide gel and the proteins were transferred to 
an Immobilon-P PVDF membrane (Millipore, Bedford, 
MA, USA), which was then blocked for 2 h at room 
temperature in PBS containing 0.05% Tween 20 and 10% 
nonfat milk. The membrane was then incubated with 
antibodies against β-actin (Sigma, 1:10000), GAPDH 
(Sigma, 1:10000), LC3 (Novus Biologicals Inc., Littleton, 
CO, 1:10000), SQSTM1/p62 (MBL international, 
1:1000), PARP (Cell Signaling Technologies, 1:1000), 
phospho-mTOR, phospho-Akt (Ser 473) (Cell Signaling 
Technologies, 1:1000), phospho-p70S6K (Cell Signaling 
Technologies, 1:1000), ABCA1 (Abcam, 1:1000), LDLR 
(Abcam, 1:5000), SREBP1 (BD, 1:1000), SREBP2 (BD, 
1:1000), CHOP (Cell Signaling Technologies, 1:1000) and 
GRP78 (Cell Signaling Technologies, 1:1000) overnight 
at 4°C in PBS containing 0.05% Tween 20 and 5% nonfat 
milk, followed by incubation for 1 h at room temperature 
with horseradish peroxidase-conjugated secondary 
antibodies (Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) in the same buffer. Blots were developed 
using a chemiluminescent detection system (ECL; GE Life 
Science, Buckinghamshire, UK).
Determination of mitochondrial membrane 
potential (MMP)
MMP was measured using a BD MitoScreen kit 
(JC-1, BD Biosciences) according to the manufacturer’s 
instructions. Briefly, 1 × 106 cells were washed, resuspended 
in 500 μL of JC-1 working solution, then incubated at 37°C 
for 15 min. Following staining, cells were washed twice 
and resuspended in 500 μL of assay buffer. Cells were 
immediately analyzed using a BD FACSCalibur flow 
cytometer. Live cells were gated and analyzed.
Measurement of ROS production
Intracellular ROS was detected by 2′,7′-dichloro-
fluorescein diacetate (DCFDA, Sigma). Cells were washed 
with PBS and incubated with DCFDA (0.25 µM) for 10 
min at 37°C. The florescence intensity was detected using 
BD Accuri™ C6 and BD Accuri™ C6 software. Untreated 
cells were used for normalization.
Evaluation of oxygen consumption and 
extracellular acidification rate of metabolic 
parameters
Metabolic responses of GBM8401 cells were 
evaluated with an Extracellular Flux Analyzer (XFe24; 
Seahorse Biosciences, North Billerica, MA) according 
to manufacturer instructions. The Extracellular Flux 
Analyzer measures oxygen consumption and extracellular 
acidification rates (ECAR) of a defined number of cells in 
a small culture media volume in real time, and monitors 
cellular responses to drug treatment. In brief, 5 × 104 cells 
were seeded in XFe24-well plates and incubated overnight 
at 37°C in a 5% CO2 humidified atmosphere, followed 
by treatment with indicated drug concentrations for 2 hr. 
After 2 hr, mitochondrial respiration was measured by 
oxygen consumption rate (OCR), and glycolysis was 
evaluated by ECAR after injecting the following inhibitors 
of mitochondrial respiration: oligomycin (inhibitor of ATP 
synthase, 1 uM), FCCP (uncoupling factor), Antimycin 
A/Rotenone (inhibitor of mitochondrial complex I of 
the ETC), and 2-deoxyglucose (2-DG; inhibitor of 
hexokinase). Basal OCR and ECAR were measured, as 
well as the changes in oxygen consumption caused by 
adding the above metabolic inhibitors. 
Immunofluorescence
U87MG and GBM8401 cells were fixed with 4% 
paraformaldehyde for 15 min at room temperature and 
the samples were twice-washed with PBS. Samples 
were then incubated for 10 mins with PBS containing 
0.25% Triton X 100 followed by PBS rinse three times 
for 5 mins. After incubating the cells with 1% BSA in 
PBST for 30 min, they were probed with a mixture of 
two primary antibodies, Cathepsin B (ab58802, Abcam, 
1:500), and LAMP1 (#9091, cell signaling, 1:500) in 
1% BSA in PBST for 1 hr at room temperature. Images 
were captured using a Zeiss LSM800 with AirScan laser 
confocal microscope. 
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Lipid and cholesterol staining
U87MG and GBM8401 cells were fixed with ice-cold 
methanol for 10 min and washed thrice with PBS, followed 
by incubation with 1 ml of 1.5 mg glycine/ml PBS for 10 
min at room temperature. Free cholesterol in cells was 
stained with 1 ml of Fillipin (Sigma-Aldrich, St. Louis, MO, 
USA) working solution (0.05 mg/ml in PBS/10% FBS) for 
2 h at room temperature. For LD staining, fixed monolayers 
with 4% paraformaldehyde were incubated with 10 μg/
ml BODIPY 493/503 (Molecular Probes, Eugene, OR, 
USA) for 30 min at room temperature. Slides were washed, 
stained with Hoechest (Cell signaling, Technology, Beverly, 
MA, USA) and visualized using fluorescent microscopy 
(Zeiss LSM800 with AirScan laser confocal microscope). 
Intracranial glioma orthotropic xenograft model
Human brain malignant glioma cells from the 
GBM8401 cell line were transformed with the luciferase 
gene (GBM8401-luc). All procedures were performed 
according to the guidelines approved by the Animal Care 
and Use Committee of the National Yang-Ming University. 
Male 6- to 8-week-old NOD/SCID mice were anesthetized 
via intraperitoneal administration of pentobarbital at 
40 mg/kg body weight. Their heads were shaved above 
the nape of the neck, scrubbed with Betadine/alcohol, 
and immobilized in a Cunningham Mouse/Neonatal 
Rat Adaptor stereotactic apparatus (Stoelting, Wood 
Dale, IL, USA). A 5-mm skin incision was made at the 
sagittal suture, then a burr hole was created, and 2 × 105 
GBM8401-lu cells in 2 μl of culture medium were injected 
stereotactically implanted into a single defined left 
hemisphere location (0.14 mm anterior and 2.0 mm lateral 
to the bregma) of each mouse brain at a 3.5 mm depth. 
The skull burr hole was then sealed with bone wax and the 
wound was flushed with iodinated alcohol. Biophotonic 
imaging was used to confirm tumor engraftment.
In vivo drug treatment
Tumor size was quantified by analyzing biophotonic 
images obtained 7 days after tumor cell implantation. 
Cohorts of 5 mice per experiment with approximately 
equivalent tumor bioluminescence were divided into four 
groups: 1) control (saline,i.p.), 2) TMZ alone (50 mg/kg, 
i.p.), 3) Chloroquine (50 mg/kg, i.p.) + Rapamycin 
(5 mg/kg, i.p.), 4) TMZ + Chloroquine + Rapamycin 
(three-drug, i.p.). Each group was treated for six days, and 
TMZ was administrated from day 3 to 6. 
In vivo imaging
After anesthesia with isoflurane (1.5 l/min oxygen in 
4% isoflurane), each mouse was injected intraperitoneally 
with 4.29 mg of freshly prepared luciferin substrate 
suspended in phosphate-buffered saline (PBS) and imaged 
10 min later using the Xenogen IVIS imaging system 
(Xenogen, Palo Alto, CA, USA), with a 1-min acquisition 
time in small-bin mode. Luciferase activity was quantified 
within a region of interest that encompassed the head of 
the mouse using Living Image Software (Xenogen, Palo 
Alto, CA, USA).
Statistical analysis
All statistical analyses were performed using Prism 
4 (GraphPad Software, Inc., La Jolla California USA, 
www.graphpad.com). The experimental and control 
groups were compared using an unpaired two-tailed 
Student’s t test. Statistical analysis was performed at the 
P < 0.05 (denoted as *).
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